Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Foghorn Therapeutics ( (FHTX) ) has issued an announcement.
In November 2025, Foghorn Therapeutics presented its strategic advancements, highlighting its collaboration with Lilly to develop FHD-909, a selective SMARCA2 inhibitor. This partnership, initiated in December 2021, includes a significant financial agreement and aims to address SMARCA4-mutant cancers. The company’s robust pipeline and strategic collaborations position it to potentially impact a large portion of the oncology market, with ongoing trials and preclinical developments indicating promising future opportunities.
The most recent analyst rating on (FHTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Underperform.
Foghorn Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and high leverage. Technical analysis also indicates bearish momentum, while valuation metrics reflect ongoing financial difficulties. The absence of earnings call data and corporate events further limits the score.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. is a leader in the biotechnology industry, focusing on chromatin biology to develop precision therapeutics. The company targets challenging areas in oncology, leveraging its Gene Traffic Control Platform® to address unmet needs in cancer treatment.
Average Trading Volume: 169,222
Technical Sentiment Signal: Sell
Current Market Cap: $226.1M
Learn more about FHTX stock on TipRanks’ Stock Analysis page.